Literature DB >> 17079296

Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements.

Stephanie A Campbell1, Matthew Mulvey, Ian Mohr, Matthias Gromeier.   

Abstract

Viral pathogenesis depends on a suitable milieu in target host cells permitting viral gene expression, propagation, and spread. In many instances, viral genomes can be manipulated to select for propagation in certain tissues or cell types. This has been achieved for the neurotropic poliovirus (PV) by exchange of the internal ribosomal entry site (IRES), which is responsible for translation of the uncapped plus-strand RNA genome. The IRES of human rhinovirus type 2 (HRV2) confers neuron-specific replication deficits to PV but has no effect on viral propagation in malignant glioma cells. We report here that placing the critical gamma(1)34.5 virulence genes of herpes simplex virus type 1 (HSV) under translation control of the HRV2 IRES results in neuroattenuation in mice. In contrast, IRES insertion permits HSV propagation in malignant glioma cell lines that do not support replication of HSV recombinants carrying gamma(1)34.5 deletions. Our observations indicate that the conditions for alternative translation initiation at the HRV2 IRES in malignant glioma cells differ from those in normal central nervous system (CNS) cells. Picornavirus regulatory sequences mediating cell type-specific gene expression in the CNS can be utilized to target cancerous cells at the level of translation regulation outside their natural context.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079296      PMCID: PMC1797477          DOI: 10.1128/JVI.00714-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals.

Authors:  I Mohr; D Sternberg; S Ward; D Leib; M Mulvey; Y Gluzman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Regulation of eIF2alpha phosphorylation by different functions that act during discrete phases in the herpes simplex virus type 1 life cycle.

Authors:  Matthew Mulvey; Jeremy Poppers; David Sternberg; Ian Mohr
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes.

Authors:  Vinagolu K Rajasekhar; Agnes Viale; Nicholas D Socci; Martin Wiedmann; Xiaoyi Hu; Eric C Holland
Journal:  Mol Cell       Date:  2003-10       Impact factor: 17.970

4.  Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.

Authors:  S Taneja; J MacGregor; S Markus; S Ha; I Mohr
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

5.  Definition of an efficient synthetic poly(A) site.

Authors:  N Levitt; D Briggs; A Gil; N J Proudfoot
Journal:  Genes Dev       Date:  1989-07       Impact factor: 11.361

6.  The vhs1 mutant form of herpes simplex virus virion host shutoff protein retains significant internal ribosome entry site-directed RNA cleavage activity.

Authors:  P Lu; H A Saffran; J R Smiley
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Intergeneric poliovirus recombinants for the treatment of malignant glioma.

Authors:  M Gromeier; S Lachmann; M R Rosenfeld; P H Gutin; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

8.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

9.  Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.

Authors:  Hideo Nakamura; Hideki Kasuya; John T Mullen; Sam S Yoon; Timothy M Pawlik; Soundararajalu Chandrasekhar; James M Donahue; E Antonio Chiocca; Richard Y Chung; Kenneth K Tanabe
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

10.  mRNA decay during herpesvirus infections: interaction between a putative viral nuclease and a cellular translation factor.

Authors:  P Feng; D N Everly; G S Read
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more
  8 in total

1.  Genetic adaptation to untranslated region-mediated enterovirus growth deficits by mutations in the nonstructural proteins 3AB and 3CD.

Authors:  Paola Florez de Sessions; Elena Dobrikova; Matthias Gromeier
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

Review 2.  Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.

Authors:  Christian Goetz; Matthias Gromeier
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-17       Impact factor: 7.638

3.  Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.

Authors:  Ryuichi Kanai; Cecile Zaupa; Donatella Sgubin; Slawomir J Antoszczyk; Robert L Martuza; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Attenuation of rabies virus replication and virulence by picornavirus internal ribosome entry site elements.

Authors:  Adriane Marschalek; Stefan Finke; Martin Schwemmle; Daniel Mayer; Bernd Heimrich; Lothar Stitz; Karl-Klaus Conzelmann
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

5.  Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites.

Authors:  Arun Ammayappan; Rebecca Nace; Kah-Whye Peng; Stephen J Russell
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

6.  Herpes simplex virus proteins ICP27 and UL47 associate with polyadenylate-binding protein and control its subcellular distribution.

Authors:  Elena Dobrikova; Mayya Shveygert; Robert Walters; Matthias Gromeier
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

7.  Anti-viral immunity in the tumor microenvironment: implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy.

Authors:  Paul J F Rider; Ifeanyi K Uche; Larissa Sweeny; Konstantin G Kousoulas
Journal:  Curr Clin Microbiol Rep       Date:  2019-11-26

Review 8.  Enterovirus infections of the central nervous system.

Authors:  Ross E Rhoades; Jenna M Tabor-Godwin; Ginger Tsueng; Ralph Feuer
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.